Orion Oyj

Director's Dealing • Nov 16, 2023

Disclosure 439697

Orion - Managers' transactions

Orion Corporation: Managers' transactions - Agendum Oy

ORION CORPORATION

MANAGERS’ TRANSACTIONS

16 NOVEMBER 2023 at 10.15 EET

Orion Corporation: Managers’ transactions – Agendum Oy

Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.

Orion Oyj - Managers' Transactions

____________________________________________

Person subject to the notification requirement

Name: Agendum Oy

Position: Closely associated person

(X) Legal person (1):Person Discharging Managerial Responsibilities In Issuer

Name: Mikael Silvennoinen

Position: Member of the Board

Issuer: Orion Oyj

LEI: 74370029VAHCXDR7B745

Notification type: INITIAL NOTIFICATION

Reference number: 43741/5/6

____________________________________________

Transaction date: 2023-11-15

Venue: NASDAQ HELSINKI LTD (XHEL)

Instrument type: SHARE

ISIN: FI0009014377

Nature of transaction: ACQUISITION

Transaction details

(1): Volume: 56 Unit price: 37.6 EUR

(2): Volume: 100 Unit price: 37.6 EUR

(3): Volume: 563 Unit price: 37.6 EUR

Aggregated transactions (3):

Volume: 719 Volume weighted average price: 37.6 EUR

____________________________________________

Transaction date: 2023-11-15

Venue: CEUX

Instrument type: SHARE

ISIN: FI0009014377

Nature of transaction: ACQUISITION

Transaction details

(1): Volume: 73 Unit price: 37.6 EUR

(2): Volume: 586 Unit price: 37.6 EUR

(3): Volume: 100 Unit price: 37.6 EUR

(4): Volume: 400 Unit price: 37.6 EUR

(5): Volume: 32 Unit price: 37.6 EUR

Aggregated transactions (5):

Volume: 1191 Volume weighted average price: 37.6 EUR

Orion Corporation

Liisa Hurme President and CEO		Olli Huotari SVP, Corporate Functions

Publisher:

Orion Corporation

Communications

Orionintie 1A, FI-02200 Espoo, Finland

http://www.orion.fi/en

http://www.twitter.com/OrionCorpIR

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and self-care products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2022 amounted to EUR 1,341 million and the company had about 3,500 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.